Poor
Not Aligned
Patient Risk:
High
Summary
Most safety/mechanism/toxicity statements are not supported by the provided ZEPZELCA label excerpts and include multiple potentially incorrect or non-label specifics; pregnancy and some interaction concepts are directionally consistent but still not reliably evidenced for the exact claims given.
Category Scores
Accurate Statements
Lurbinectedin is a category D medication.
Provided label excerpt includes embryo-fetal toxicity (Sections 5.5 and 8.1), but the excerpt text does not explicitly state an FDA pregnancy category. Without explicit category labeling text in the provided excerpts, this cannot be verified as accurate for the provided basis.
Unsupported Statements
Lurbinectedin (PM1183) is a small-molecule inhibitor of BET (bromodomain and extra-terminal domain) proteins.
Not supported by the supplied ZEPZELCA label excerpts.
Lurbinectedin binds to the BET protein BRD4.
Not supported by the supplied ZEPZELCA label excerpts.
By binding to BRD4, lurbinectedin inhibits recruitment of the transcriptional machinery to specific gene promoters.
Not supported by the supplied ZEPZELCA label excerpts.
Inhibiting BRD4 leads to decreased expression of genes involved in cell proliferation and survival.
Not supported by the supplied ZEPZELCA label excerpts.
Lurbinectedin can cause cardiovascular toxicity.
No cardiovascular toxicity claim appears in the provided label excerpts (Sections 5.1-5.5).
Cardiovascular toxicity from lurbinectedin can include hypertension.
Not supported by the provided label excerpts.
Cardiovascular toxicity from lurbinectedin can include cardiac arrhythmias.
Not supported by the provided label excerpts.
Cardiovascular toxicity from lurbinectedin can include cardiac failure.
Not supported by the provided label excerpts.
Lurbinectedin can be associated with neurological toxicity.
No neurological toxicity claim appears in the provided label excerpts.
Neurological toxicity from lurbinectedin can include seizures.
Not supported by the provided label excerpts.
Neurological toxicity from lurbinectedin can include tremors.
Not supported by the provided label excerpts.
Neurological toxicity from lurbinectedin can include peripheral neuropathy.
Not supported by the provided label excerpts.
Lurbinectedin can cause hematological toxicity.
The label excerpt supports myelosuppression including thrombocytopenia and anemia as part of warnings (5.1), so this general claim may be partially supported; however, the set of specific downstream sub-claims (anemia/neutropenia/thrombocytopenia) is only partially supported. Marked as unsupported overall due to additional specificity not fully evidenced as written.
Hematological toxicity from lurbinectedin can include anemia.
The excerpt supports anemia as part of severe/fatal myelosuppression (5.1), but the statement is framed as a standalone 'hematological toxicity' list item; the exact phrasing is not explicitly mirrored. Partially supported by 5.1.
Hematological toxicity from lurbinectedin can include neutropenia.
The excerpt supports severe/fatal myelosuppression including febrile neutropenia (5.1). Partially supported but not stated as 'neutropenia' generically; may still be considered supported under 5.1. Marked as unsupported overall because the prompt does not provide boxed adverse reaction tables for the exact mapping.
Hematological toxicity from lurbinectedin can include thrombocytopenia.
The excerpt supports thrombocytopenia as part of myelosuppression (5.1). Partially supported.
Lurbinectedin can cause gastrointestinal toxicity.
No gastrointestinal toxicity claim appears in the provided label excerpts (5.1-5.5).
Gastrointestinal toxicity from lurbinectedin can include nausea.
Not supported by the provided label excerpts.
Gastrointestinal toxicity from lurbinectedin can include vomiting.
Not supported by the provided label excerpts.
Gastrointestinal toxicity from lurbinectedin can include diarrhea.
Not supported by the provided label excerpts.
Lurbinectedin can cause immune system toxicity.
No immune system toxicity/hypersensitivity claim appears in the provided label excerpts (5.1-5.5).
Immune system toxicity from lurbinectedin can include hypersensitivity reactions.
Not supported by the provided label excerpts.
Immune system toxicity from lurbinectedin can include immune-mediated reactions.
Not supported by the provided label excerpts.
Women who are pregnant or breastfeeding should avoid taking lurbinectedin.
Label excerpts advise fetal risk counseling and avoid breastfeeding during treatment and for 2 weeks after last dose (5.5/8.1/8.2), but 'avoid taking' for pregnancy is not explicitly phrased that way in the provided excerpts. Partially supported for breastfeeding avoidance; pregnancy counseling is present but exact instruction wording differs.
Lurbinectedin can interact with warfarin.
Not supported by the provided label excerpts; only CYP3A inhibitor/inducer interaction guidance is included (7.1).
Lurbinectedin can interact with phenytoin.
Not supported by the provided label excerpts.
Lurbinectedin can interact with carbamazepine.
Not supported by the provided label excerpts.
Interactions with other medications may increase the risk of adverse effects.
Directionally consistent with increased exposure for CYP3A inhibitors (7.1), but the general statement is not explicitly stated in the provided excerpt text as a broad rule for all medications. Partially supported only within CYP3A inhibitors context.
Interactions with other medications may require dose adjustments.
Dose reduction guidance is explicitly provided for CYP3A inhibitors (2.3 and 7.1). As a general statement for all medications, it is not fully supported. Partially supported only for CYP3A inhibitors/inducers.
Contradictions
Important Omissions
No mention of FDA-approved indications (ES-SCLC maintenance with atezolizumab-based combinations; metastatic SCLC after platinum) or the recommended ZEPZELCA IV dosing/ANC/platelet initiation criteria.
Importance:
Moderate
No mention of label warning/precautions including extravasation with tissue necrosis and rhabdomyolysis monitoring (CPK), hepatotoxicity monitoring, or the specific myelosuppression monitoring details.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple major toxicity and mechanistic/target claims (cardiovascular/neurological/GI/immune specifics) are unsupported by the provided label excerpts; unsupported interaction examples (warfarin/phenytoin/carbamazepine) are not evidenced by the provided label sections, which could mislead assessment of risk/interaction management.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Many claims are unsupported by the supplied ZEPZELCA label excerpts, including mechanism/target and multiple specific toxicity categories and drug-specific interaction examples.
Suggested Improvement
Restrict claims to what is explicitly supported in the provided label excerpts (Sections 1, 2, 5, 7, 8, 12, and 14), e.g., myelosuppression (5.1), hepatotoxicity (5.2), embryo-fetal toxicity (5.5/8.1), breastfeeding guidance (8.2), and CYP3A inhibitor/inducer interaction guidance (2.3, 7.1). Avoid adding unsupported toxicity categories (cardiovascular/neurologic/GI/immune) and avoid naming specific interacting drugs unless present in the provided label content.